3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Breast Neoplasms
25
Breast Neoplasms, Male
6
Triple Negative Breast Neoplasms
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lung Neoplasms
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Thoracic Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Interventions
belinostat
2
rucaparib
1
pembrolizumab
1
futibatinib
1
Nivolumab
1
Mass Spectrometry
1
Imatinib Mesylate
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Chromatography, High Pressure Liquid
1
BI 2536
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leiomyosarcoma
×
Erlotinib Hydrochloride
×
Breast
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled